Shanghai MicroPort Endovascular MedTech (Group) Co., Ltd. ("Endovastec™"), a subsidiary of MicroPort Scientific Corporation ("MicroPort®"), was founded in Shanghai SIMZ Century Medicine Park in 2012. Endovastec™ was granted Shanghai High-tech Enterprises, Shanghai Science and Technology Little Giant Enterprise and the first batch of Specialized and New "Little Giant" Enterprise, AAA-level Credit Enterprise and Multinational R&D Center in China. Endovastec™ was listed on the STAR Market (Stock code: 688016) of the Shanghai Stock Exchange on July 22, 2019.

Endovastec™ is committed to R&D, manufacturing, and sales of aortic and peripheral vascular interventional devices, and our main products are thoracic and abdominal aortic stent grafts, stent grafts in surgical operation, drug coated PTA balloon catheters, and PTA balloon catheters etc. The Project of "Key Technology Development and Large-scale Industrialization of Large Vascular Stent Graft Series products" won the second prize of National Scientific and Technological Progress Award, and the Project of "Development and Industrialization of Key Technologies in Minimally Invasive Treatment of Aortic Diseases" won the First Prize of Shanghai Science and Technology Progress Award. With its 7 self-developed products have been approved by the national "Special Approval Procedure of Innovative Medical Device", Endovastec is staying ahead in the field. Endovastec™ has 5 approved thoracic and abdominal aortic stent grafts products for aortic intervention, and is a company with comparatively complete product lines in subdivisions around the globe.

Endovastec™ is committed to provide trustworthy and universal access to state-of-the-art solutions of prolonging and reshaping all lives, and to build a people centric enterprise ranking as a global leader of evolving and emerging medical technologies through continuous innovation.